Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-107P corresponds to a pseudogene related to the U1 small nuclear RNA (snRNA) family, which is essential for the accurate splicing of pre-mRNA in human cells. Unlike the canonical U1 snRNA loci (e.g., RNU1-1), U1 snRNA pseudogenes such as RNU1-107P possess sequence similarity but are generally considered nonfunctional due to mutations, deletions, or other sequence changes that disrupt canonical processing. While some pseudogenes are transcriptionally active and can regulate gene expression via RNA mechanisms, RNU1-107P itself is not known to encode a functional snRNA or play a direct biological role. It has not been associated with human disease or targeted therapeutically. The locus is annotated for comparative genomics, gene expression, and snRNA sequence diversity studies[1][5]. RNU1-107P is accurately classified as a pseudogene—not a therapeutic target, receptor, enzyme, or molecule relevant to drug development. Any designation of RNU1-107P as a druggable or pharmacological target would be incorrect[1][5].
None; not applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 107, pseudogene (RNU1-107P).